AR
ARTL.US Artelo Biosciences Inc
- Market cap
- USD 1.13M
- P/E
- -
- P/B
- 0.23x
- ROE
- -152.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ARTL.US undervalued?
Graham numberThe Graham number of Artelo Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Artelo Biosciences Inc fundamental analysis
No fundamental analysis for Artelo Biosciences Inc yet.
Artelo Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Artelo Biosciences Inc
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxi…
Full company profileArtelo Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Artelo Biosciences Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - |
| Operating Income | -29.7K | -233K | -2.34M | -3.21M | -4.69M | -7.44M | -10.3M | -9.93M | -10.1M | -11.4M | -9.31M |
| EBITDA | -29.7K | -233K | -2.34M | -4.22M | -4.69M | -7.44M | -10.1M | -9.29M | -9.83M | -12.5M | -9.36M |
| Net Income | -29.7K | -235K | -2.34M | -2.17M | -4.66M | -7.44M | -10.1M | -9.29M | -9.83M | -12.9M | -9.54M |
| EPS | -8.39 | -58 | -495 | -270 | -339 | -108 | -64 | -9.41 | -9.15 | -49 | -17 |
| Balance Sheet | |||||||||||
| Total Assets | 3.59K | 574K | 397K | 6.48M | 4.38M | 12.6M | 20.4M | 13.0M | 4.70M | 2.80M | 6.68M |
| Total Liabilities | 17.4K | 29.4K | 532K | 1.02M | 501K | 593K | 1.02M | 1.29M | 1.84M | 4.07M | 439K |
| Shareholders' Equity | -13.8K | 545K | -135K | 5.46M | 3.88M | 12.0M | 19.4M | 11.8M | 2.86M | -1.27M | 6.24M |
| Cash & Short-term Investments | 3.59K | 573K | 337K | 4.42M | 2.14M | 10.1M | 17.5M | 10.4M | 2.34M | 600K | 4.44M |
| Total Debt | - | - | - | - | - | 95.0K | 63.0K | 23.0K | 104K | 678K | 40.0K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -18.5K | -217K | -1.61M | -2.79M | -4.35M | -6.14M | -8.01M | -8.21M | -8.35M | -8.52M | -11.8M |
| Capital Expenditure | 845.00 | 845.00 | 845.00 | 1.50M | 1.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.33 |
| Free Cash Flow | -18.5K | -217K | -1.61M | -4.29M | -4.35M | -6.14M | -8.01M | -8.21M | -8.35M | -8.52M | -11.8M |
| Ratios | |||||||||||
| ROE | - | -43.1% | - | -39.8% | -120.1% | -61.8% | -52.0% | -79.0% | -343.9% | - | -152.9% |
| ROA | -827.0% | -40.9% | -590.3% | -33.5% | -106.4% | -58.9% | -49.4% | -71.2% | -209.2% | -459.8% | -142.9% |
| Debt to Equity | - | - | - | - | - | 0.01x | 0.00x | 0.00x | 0.04x | - | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Artelo Biosciences Inc dividends
Artelo Biosciences Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:9 on Aug 31, 2026.
Who owns Artelo Biosciences Inc
- Insiders 0.11%
- Institutions 5.69%
- Public & others 94.21%
- Shares outstanding 548K
- Free float 510K
Top funds holding ARTL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 1.48K | 0.27% | +0.14% | Sep 2026 |
| Fidelity Series Total Market Index | 1.00 | 0.00% | -96.00% | Sep 2026 |
Top institutions holding ARTL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jane Street Group LLC | 66.3K | 1.35% | +407.23% | Jun 2026 |
| Geode Capital Management, LLC | 13.9K | 0.28% | 0.00% | Jun 2026 |
| StoneX Group Inc | 12.4K | 0.25% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 10.1K | 0.21% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 8.44K | 0.17% | +198.48% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 3.14K | 0.06% | 0.00% | Jun 2026 |
| UBS Group AG | 2.80K | 0.06% | 0.00% | Jun 2026 |
| TD Waterhouse Canada Inc | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Rothschild Wealth Partners | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Danske Bank A/S. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Kathmere Capital Management, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Clear Street Group Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 0.00 | 0.00% | -100.00% | Jun 2026 |
Artelo Biosciences Inc company profile
- Company name
- Artelo Biosciences Inc
- Ticker
- ARTL.US
- Exchange
- USA Stocks
- Listed since
- Nov 14, 2017
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 7
- Fiscal year end
- December
- Address
- 505 Lomas Santa Fe, Solana Beach, CA, United States, 92075
- Phone
- 858 925 7049
- Website
- artelobio.com
About Artelo Biosciences Inc
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Artelo Biosciences Inc management
5- Mr. Gregory D. Gorgas M.B.A.President, CEO, Secretary & Director · born 1963
- Mr. Mark E. Spring CPACFO, Treasurer, Principal Financial Officer & Principal Accounting Officer · born 1959
- Dr. Andrew Yates Ph.D.Senior VP & Chief Scientific Officer
- Dr. Steven D. Reich M.D.Chief Medical Officer · born 1946
- Mr. Jason H. BaybuttSenior Vice President of Finance · born 1972